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Abstract. We investigated IL-10 and IL-6 production in amyloid- (A) stimulated peripheral blood mononuclear cells (PBMCs)
in twenty Alzheimer’s disease (AD) patients with slow progression, eleven with fast progression, and twenty age-matched
controls. Promoter polymorphisms in IL-10 (position −592, −819, −1082), IL-6 (−174), transforming growth factor-1 (TGF-
1) (−10, −25), interferon- (IFN-) (−874), and tumor necrosis factor- (TNF-) (−308) genes were analyzed. IL-10
production after A stimulation was high in PBMCs from slow decliners and almost completely abrogated in fast decliners.
Association between AA IFN- low-producing genotype and fast progression was demonstrated. Investigations in a larger
sample will clarify these findings.
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INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial dis-
ease and there is increasing evidence that the immune
system plays a critical role in the clinical symptoms
[1–4]. Interleukin-10 (IL-10) is well characterized as
an anti-inflammatory cytokine, with potent suppres-
sive effects in preventing autoimmune disease [5]. The
main function of IL-10 seems to be to limit and termi-
nate the inflammatory signal in cells such as monocytes
and macrophages [6, 7]. Studies have shown that IL-
10 is associated with cancer, AD, systemic sclerosis,
type 2 diabetes, ischemic stroke, atherosclerosis, car-
diovascular disease, ankylosing spondylitis, asthma,
rheumatoid arthritis, and prostate hyperplasia [8–16].
Although considered to be immunosuppressive in
function, the use of IL-10 as a potential therapeutic has
given mixed results, suggesting a more complex role
in immune regulation. The effect of IL-10 on B cells
may be stimulatory rather than suppressive [17, 18].
To date, −1082AA low IL-10 producer genotype
was associated with higher risk of developing AD,
whereas −1082GG high IL-10 producer genotype fre-
quency is higher in centenarians [8, 19–23]. A study
following subjects with mild cognitive impairment
(MCI) has shown that MCI converting to AD showed
a higher frequency of allele A and −1082AA IL-10
genotype compared with stable MCI or those who
convert to vascular dementia suggesting a role of
−1082AA polymorphism in converting from MCI to
AD [23]. Ex vivo studies confirmed this link between
AD and decreased IL-10 production [20, 21].
The objective of our study was to further investigate
the role of IL-10 in AD, in combination with other
cytokine gene polymorphisms (IL-6, IL-10, TNF-,
TGF-1, and IFN-).
MATERIALS AND METHODS
A total of 51 individuals were enrolled in the study:
20 healthy elderly (controls) and 31 AD patients
(Table 1). Subjects diagnosed with AD fulfilled the
criteria of dementia and AD defined by NINCDS-
ADRDA [24]. All individuals were Caucasians living
in Milan or Paris and belonged to larger populations of
outpatients.
The criteria for the diagnosis of normal cognition
were: 1) no active neurological or psychiatric disorder;
2) no ongoing medical problems or related treatments
interfering with cognitive function; 3) a normal neu-
rological exam; 4) no psychoactive medications; and
5) the ability to live and function independently in the
Table 1
Demographic and clinical characteristics of Alzheimer’s patients and age-matched controls
AD patients
Controls AD slow AD fast Total p value
(n = 20) (n = 20) (n = 11) (n = 31)
Demographic data
Age, median 78.2 80.5 78.8 79.5 ns
(range) (63.7–96.2) (71.2–88.0) (74.5–86.5) (71.2–88.0)
Ethnicity, n (%)
African 0 (0%) 0 (0%) 1 (9%) 1 (3%) ns
Caucasian 20 (100%) 20 (100%) 10 (91%) 30 (97%)
Alzheimer’s disease data
Age of AD onset, NA 77.0 77.4 77.0 ns
median (range) (66.4–86.3) (70.6–83.6) (66.4–86.3)
Duration of the NA 2.8 2.9 2.9 ns
disease before (1.4–9.4) (1.4–6.4) (1.4–9.4)
recruitment (y), median (range)
a: 4.66E–7
MMSE score∗∗, 30 21 14 17 b: 2.81E–6
median (range) (26–30) (8–25) (5–21) (5–25) c: 4.33E–5
d: 0.001
Calculated MMSE over 2 y, 0.0 –0.5 –7.2 –2 d: 5,6E–6
median (range) (–0.9 – 0.9) (–3.5 – 1.2) (–16.1 – –3.8) (–16.1 – 1.2)
Unknown 18/20 0 0 0
AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; NA, not applicable; ns, not significant; y, years. AD slow and AD fast stand
for AD patients displaying slow and fast disease progression, respectively. Regarding statistical analysis, demographic and clinical data were
analyzed using Kruskall-Wallis test for multiple comparisons or Mann–Whitney rank sum test for comparing two groups. Comparison of AD
treatment was done with χ² test, Fisher’s exact test, or the Freeman-Halton extension of the Fisher exact probability test. a, total age-matched
controls to total AD patients comparison, b, total age-matched controls to AD slow comparison, c, total age-matched controls to AD fast patients
comparison, d, AD slow to AD fast patients comparison. MMSE score at the end of the follow up period.
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community. Individuals affected by cancer or cardio-
vascular diseases were excluded. At recruitment, none
of the subjects showed clinical signs of inflammation.
All participants and their relatives gave informed con-
sent and the respective ethics committees approved the
study protocol.
At baseline, physical, neurological, and neuropsy-
chological examinations were performed for all
patients together with clinical history, computed
tomography, or magnetic resonance imaging scan,
and cognitive testing using the Mini-Mental State
Examination (MMSE). Laboratory analyses included
routinely biochemical tests. After a two-year period
follow-up, AD patients were retrospectively evalu-
ated and AD progression rate was calculated by using
deltaMMSE score (MMSE at recruitment - MMSE
after the two-year follow-up period). Patients were cat-
egorized as slow-progressing AD if deltaMMSE ≤ 3
points and no appearance of new cognitive disorders
(AD slow) or fast-progressing AD if deltaMMSE ≥ 5
points and appearance of other AD related disorders
(AD fast). Blood from all individuals was collected
at the same time in the morning and employed
for biochemical tests and PBMCs isolation. PBMCs
were cultured in medium, medium+LPS (1 ng/ml),
or medium+pool of three A peptides: 1g/ml of
fragment (1–16), 10g/ml of fragment (25–35), and
25g/ml of fragment (1–40) (Innovagen, Lund, Swe-
den). IL-10 production was measured with ELISA
(Ready-SET-Go! test; eBioscience, Paris, France).
Statistical analyses were conducted using softwares
R and SPSS. As samples were independent and not
normally distributed, Kruskall-Wallis test for multi-
ple comparisons, Mann–Whitney rank sum test for
comparing two groups and Wilcoxon sign test for inter-
group comparison (of two medians observed in paired
series) were used. For proportion comparison, χ² test
(if N > 5 or at least 80% of the cells have an expected
frequency of 5 or greater, and that no cell has an
expected frequency smaller than 1.0) and Fisher’s exact
test (if N < 5 in the case of a 2×2 contingency table) or
the Freeman-Halton extension of the Fisher exact prob-
ability test (if N < 5 in the n × m contingency table with
n and m > 2) were used.
RESULTS
The median (Table 1) and mean MMSE at the
blood sample collection was higher among AD slow
than AD fast (mean values: 19.6 ± 4.6, and 12.3 ± 5.4,
p < 0.05). Frequencies of patients with or without AD
targeted therapies were statistically similar between
the two groups (data not shown).
The analysis did not show any statistically signif-
icant changes in biochemical analysis in relation to
AD and/or progression. Co-morbid conditions were
not different between controls and AD patients, and
between controls and AD slow or AD fast (data
not shown). Significant increase of IL-10 produc-
tion in PBMCs after LPS-stimulation was showed
in AD patients and controls with no significant dif-
ferences between the groups (controls: 20.9 ± 6.0
versus 484.6 ± 248.9; p = 7.6 106, total AD patients:
19.4 ± 6.8 versus 704.4 ± 238.0; p = 1.8 106, AD slow:
23.2 ± 5.7 versus 671.0 ± 285.5; p = 9.6 105, AD fast:
16.2 ± 4.9 versus 797.3 ± 223.4; p = 0.002, Fig. 1A).
A-stimulated IL-10 production analysis showed a sig-
nificant increase of antigen-specific IL-10 production
compared with resting production in AD with slow pro-
gression (40.7 ± 13.7 versus 59.0 ± 27.0; p = 0.004,
Fig. 1B). Interestingly, AD fast did not show any dif-
ference, suggesting a lack of response to A stimulus
(39.7 ± 14.4 versus 42.2 ± 22.4; p = 0.94).
No significant differences were shown in IL-10 and
IL-6 plasma concentrations between AD and controls,
probably due to the small sample size (data not shown).
Despite there being no significant differences in
genotype and allele frequencies of –1082 G/A (p = 0.61
and p = 0.33, respectively), –819 C/T and –592 C/A
SNPs (p = 0.47 and p = 0.24, respectively), there is a
trend toward AD patients having a higher frequency
of the low/intermediate IL-10-producing genotypes
(−1082 AA/GA: 77%) and lower frequency of
−1082GG genotype (23%) compared to controls (65%
and 35%, respectively) [19, 20, 23, 25, 26]. AD fast
showed a lower frequency of high IL-10 producing
genotype compared to AD slow (25.0% versus 18.2%).
In addition, GG genotype could confer a slower pro-
gression rate of the disease.
Analysis of the IFN- genotype distribution
between controls and AD showed the highest fre-
quency of AA genotype (81.8%), associated with
decreased IFN- levels [27] in AD fast (p = 0.003)
compared to the other groups (25% in AD slow and
25% in controls). Similarly, the A allele was signif-
icantly more represented among AD fast (p = 0.042)
(81.1% versus 55% in AD slow and 50% in controls).
Distribution of genotype and allele frequencies of IL-6
(−174), TNF- (−308), and TGF-1 (−10 and −25)
did not differ (data not shown).
Despite the not significant result obtained for the
ApoE 4 distribution (p = 0.08), the groups show clear
differences in the numbers of 4 carriers (31.6%,
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Fig. 1. Ex vivo, LPS- and A-induced IL-10 production by PBMCs
of AD patients and age-matched controls. PBMCs (3.106 cells / ml)
from AD patients (n = 30) and age-matched controls (n = 18) were
cultured either in complete medium alone (open symbol), supple-
mented with 1 ng/ml of LPS (full symbol, A) during two days or
supplemented with a pool of three A peptides: 1g/ml of fragment
(1-16), 10g/ml of fragment (25–35), and 25g/ml of fragment
(1–40) (full symbol, B) during five days. Results have been showed
as scatter plot and the median value is indicated by a black plain line.
Kruskall-Wallis and Mann-Whitney U-test were applied for inter-
group comparison. For intragroup comparison of IL-10 production,
Wilcoxon sign test was used as it was comparison of two medians
observed in paired series.
55.6%, and 60% of 4 carriers, respectively in controls,
AD slow, and AD fast).
We report a significantly increased A specific
PBMCs IL-10 and IL-6 productions (Fig. 1 and
Supplementary Material) in AD slow (p = 0.004 and
p = 0.01 for IL-10 and IL-6). Abrogation of IL-10 spe-
cific production has been demonstrated in AD fast
suggesting impaired response to A stimulus in these
patients.
DISCUSSION
In accordance with our findings, some authors
have reported an increase of IL-10 and IL-1ra, which
should balance the higher in vitro production of
pro-inflammatory cytokines [28, 29]. However, some
studies demonstrated a reduction of both pro- and anti-
inflammatory cytokines [30, 31], suggesting a general
impairment of immune functions in AD. Other stud-
ies demonstrated a decrease of IL-10 and an increase
of pro-inflammatory cytokines IL-1, IL-6, and IFN-
 [21, 32–34]. This variability could be explained by
methodological differences among studies, including
inclusion criteria of both AD patients and healthy con-
trols and methods of mitogen- or A-stimulation. Ours
is the first study in which the rate of AD disease pro-
gression has been taken into account.
Data on IL-10 −1082 polymorphism suggested an
association with AD risk indicating protective effect
of −1082GG genotype [19, 26]. Our data suggest that
GG genotype (associated with highest IL-10 produc-
tion) could confer additional protection from a fast
progression rate of AD.
Studies have shown that IFN- −874 TA polymor-
phism does not represent a risk factor for AD [35–39].
However, our data suggests that this polymorphism
could be involved in disease progression, with high
IL-10 production and high IFN- genotype [27] con-
ferring a slower AD progression. The presence of high
producer T allele is associated with highest IFN-
mRNA expression [40] and blood levels both at base-
line and after PBMCs stimulation [41]. Our results
show that the frequency of the low producer A allele
of IFN- is increased in patients with fast progression.
Our data suggest that fast AD progressing lack
ability to mount effective anti-inflammatory response
to A contributing to the de-regulation of their
immune system. Elucidation of these mechanisms
using larger study group may shed new light
on the potential avenues to manage the disease
progression.
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